Navigation Links
Latest Information on Obese Patients with Type 2 Diabetes and LAP-BAND System
Date:7/25/2011

LOS ANGELES, July 25, 2011 /PRNewswire/ -- Bariatric surgery is recommended by IDF, the International Diabetes Foundation, for obese patients with type 2 diabetes. According to a new IDF position paper, bariatric surgeries for these obese patients can reduce health care costs in the long run. According to IDF, the surgery often normalizes blood glucose levels and reduces or even eliminates the need for medication. LAP-BAND® Adjustable Gastric Banding system is the original alternative to more invasive gastric bypass surgery and has a history of proven success in helping patients reach their weight loss goals for the long term.

According to an estimate by IDF, for a person in United States who is diagnosed at the age 50, the lifetime cost of diabetes is $172,000, and for a person diagnosed at age 30 this cost would be $305,000. More than 60% of these costs are incurred in the first decade after diagnosis.

With the new IDF guidelines, patients with type 2 diabetes would warrant bariatric surgery when their BMI is higher than 35; or when their BMI is between 30 and 35 when their diabetes cannot be controlled by lifestyle changes and medication. IDF has said that trials are needed to compare surgical procedures. However, the new recommended indications for bariatric surgery for patients who are both diabetic and obese match those announced by US Food and Drug Administration (FDA) for expanded use of LAP-BAND® system.

LAP-BAND® reduces the amount of the food the stomach can hold at one time, which helps to gradually lose weight and keep it off. LAP-BAND® has been proven to result in steady and healthy weight loss and to help patients keep the weight off for a longer period of time compared to non-surgical treatments.  

LAP-BAND® Adjustable Gastric Banding system is the only FDA-approved gastric banding system for people with a body mass index (BMI) of 30 or higher who suffer from one or more obesity-related comorbid health conditions. To read more articles about LAP-BAND® system and diabetes, visit  1 800 Get Thin at http://www.1800getthin.com.

PR by http://www.seocompanyca.com


'/>"/>
SOURCE 1 800 Get Thin
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Latest Releases of Elektas XiO Planning and Focal Contouring Systems Designed to Increase Efficiency in Planning Therapy for Patients with Cancer
2. Enzymatics Reports Latest Growth Figures; Confirms Massachusetts Emerging Role as Leading Bio-manufacturing Center
3. Latest Molecular Diagnostics Technology Aids German Hospital in Management of European E. coli Crisis
4. Statement From Volcano Corporation on Latest St. Jude Lawsuit
5. Latest Clinical Evidence Supports Promising Outlook for Low-Dose Molecular Breast Imaging (MBI)
6. Pharma Elite to Unveil Latest Industry News/Program Agenda with 70+ Expert Speakers at Exclusive Event: Pharma CI Conference, September 13-14, 2011 in New Jersey
7. Transgenomic, Inc. Presents Its Latest Technology at the BIT Life Sciences World DNA and Genome Day Conference, Dalian, China
8. LATEST Medical Introduces New Kind of Patient Information Web Site - LATESTBreastCancer.com
9. Varian Medical Systems to Exhibit the Latest Digital Image Detectors, X-Ray Tubes and Cancer Treatment Technologies at the CMEF Show in Shenzhen, China
10. NewCardio Invited to Present Latest QTinno Performance Improvements at FDA-Sponsored Conference on Cardiovascular Safety in Drug Development
11. Ingenuity Announces RNA-Sequencing Workflow Support and First-of-Its-Kind microRNA Filtering Capability With Latest Release of IPA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... 23, 2017 ArisGlobal, a leading ... announces agClinical 3.3, the latest version of its comprehensive ... science organizations to confidently and efficiently meet new compliance ... the electronic trial master file so that compliance is ... ...
(Date:1/23/2017)... 2017  HOPE BIOSCIENCES announced today that it ... commercialize nuc -gemcitabine™ (APTA-12/HOPE-888) through a licensing ... nuc -Gemcitabine consists of Antisoma,s ... found on many cancer cells, and dFdCMP, an ... conjugates) or SMDCs (small molecule drug conjugates), which ...
(Date:1/23/2017)... 23, 2017  Therabron Therapeutics, Inc., a clinical-stage ... in respiratory care, today announced that the European ... has granted Orphan Drug Designation for Therabron,s CG367 ... Syndrome (BOS).  "We are pleased to ... to treat patients diagnosed with BOS following lung ...
Breaking Medicine Technology:
(Date:1/24/2017)... ... January 23, 2017 , ... The TouchPoint Solution, ... who entered metrics into the product’s app. The data replicates and validates ... that within just 30 seconds of using Buzzies, people experienced a 74 percent ...
(Date:1/24/2017)... Michigan (PRWEB) , ... January 24, 2017 , ... The ... other advocates for drug and alcohol awareness, have worked with communities to designate the ... year, observed January 23-29, 2017, the theme is “Shatter the Myths.” As a ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... localization services for life science companies, has achieved ISO 17100:2015 certification following ... America. ISO 17100 is the globally recognized standard that establishes guidance for ...
(Date:1/23/2017)... ... 23, 2017 , ... The iaedp Foundation, recognized for its ... who treat the full spectrum of eating disorder problems, proudly announces the addition ... of the leading eating disorder treatments centers located throughout the U.S. As partners ...
(Date:1/23/2017)... ... 2017 , ... Sharon Kleyne, America’s leading water researcher, advocate and feared enemy ... of making new water infrastructure a number one priority. “As we usher in a ... infrastructure to become a top priority of our new political change agents.” Kleyne pointed ...
Breaking Medicine News(10 mins):